Royal Bank Of Canada Arrowhead Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

$422 Billion
Q1 2024

A detailed history of Royal Bank Of Canada transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 35,109 shares of ARWR stock, worth $880,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,109

Previous 50,273 30.16%

Holding current value

$880,182

Previous $1.54 Million 34.72%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $412,612 - $598,674	-15,164 Reduced 30.16%	35,109 $1 Million
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $348,443 - $510,009	16,436 Added 48.57%	50,273 $1.54 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $274,156 - $377,541	-10,464 Reduced 23.62%	33,837 $909,000
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $581,975 - $957,160	23,131 Added 109.26%	44,301 $1.58 Million
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $1.47 Million - $2.38 Million	-61,888 Reduced 74.51%	21,170 $537,000

Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $526,456 - $762,609	18,802 Added 29.26%	83,058 $3.37 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $106,193 - $173,143	3,584 Added 5.91%	64,256 $2.12 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $16,618 - $30,264	598 Added 1.0%	60,672 $2.14 Million
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $1.1 Million - $1.95 Million	-27,822 Reduced 31.65%	60,074 $2.76 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $1 Million - $1.42 Million	17,263 Added 24.44%	87,896 $5.83 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $581,464 - $846,201	9,960 Added 16.42%	70,633 $4.41 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $3.77 Million - $5.48 Million	60,673 New	60,673 $5.03 Million

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.65B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Arrowhead Pharmaceuticals, Inc. Transaction History